LEAP-008 evaluating lenvatinib with or without pembrolizumab in patients with metastatic NSCLC who progressed after receiving anti–PD-(L)1 therapy and platinum-based chemotherapy (Table 2). Here, CD274 is linked to non-small cell lung carcinoma.